Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Use of psilocybin (“mushrooms”) among US adults: 2015–2018
R. Andrew Yockey, Keith A. King
Journal of Psychedelic Studies (2021) Vol. 5, Iss. 1, pp. 17-21
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Adolescent and adult time trends in US hallucinogen use, 2002–19: any use, and use of ecstasy, LSD and PCP
Ofir Livne, Dvora Shmulewitz, Claire Walsh, et al.
Addiction (2022) Vol. 117, Iss. 12, pp. 3099-3109
Open Access | Times Cited: 53
Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review
Aryan Sarparast, Kelan Thomas, Benjamin Malcolm, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1945-1976
Open Access | Times Cited: 52
Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption
Emma Morton, Kimberly Sakai, Amir Ashtari, et al.
Journal of Psychopharmacology (2022) Vol. 37, Iss. 1, pp. 49-60
Open Access | Times Cited: 44
Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
Sandeep M. Nayak, Hillary Jackson, Nathan D. Sepeda, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 37
On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review
Richard J. Zeifman, Nikhita Singhal, Leah Breslow, et al.
ACS Pharmacology & Translational Science (2021) Vol. 4, Iss. 2, pp. 436-451
Open Access | Times Cited: 45
Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes
Richard Matzopoulos, Robert Morlock, Amy Morlock, et al.
Frontiers in Psychiatry (2022) Vol. 12
Open Access | Times Cited: 30
Naturalistic Psychedelic Use: A World Apart from Clinical Care
Nicolas G. Glynos, Christopher W. Fields, Julie Barron, et al.
Journal of Psychoactive Drugs (2022) Vol. 55, Iss. 4, pp. 379-388
Closed Access | Times Cited: 30
A Transformative Trip? Experiences of Psychedelic Use
Logan Neitzke‐Spruill, Caroline Beit, Jill O. Robinson, et al.
Neuroethics (2024) Vol. 17, Iss. 2
Open Access | Times Cited: 5
Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users’ Patterns of Use and Perceived Effects
Carrie Cuttler, Amanda Stueber, Jonathan J. Simone, et al.
Journal of Psychoactive Drugs (2025), pp. 1-13
Closed Access
American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey
Brian S. Barnett, Miranda Arakelian, David S. Beebe, et al.
Psychedelic Medicine (2023) Vol. 2, Iss. 1, pp. 1-9
Closed Access | Times Cited: 13
Tripping into Treatment: Comparing Initial and Current Motivations for Psychedelic Use
Daniel J. Kruger, Janice K. Albrecht, Jacob S. Aday, et al.
Journal of Psychoactive Drugs (2025), pp. 1-7
Closed Access
Psychedelic Microdosing among Young Adults from Southern California
Alyssa F. Harlow, Peter S. Hendricks, Adam M. Leventhal, et al.
Journal of Psychoactive Drugs (2024), pp. 1-12
Closed Access | Times Cited: 3
“How Do I Learn More About this?”: Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics
Daniel J. Kruger, Oskar Enghoff, Moss Herberholz, et al.
Journal of Psychoactive Drugs (2023) Vol. 55, Iss. 5, pp. 631-639
Closed Access | Times Cited: 8
ARC: a framework for access, reciprocity and conduct in psychedelic therapies
Meg J. Spriggs, Ashleigh Murphy-Beiner, Roberta Murphy, et al.
Frontiers in Psychology (2023) Vol. 14
Open Access | Times Cited: 8
“A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use
Meghan DellaCrosse, Mollie Pleet, Emma Morton, et al.
PLoS ONE (2022) Vol. 17, Iss. 12, pp. e0279073-e0279073
Open Access | Times Cited: 12
Examining differences in the effects and contexts of naturalistic psilocybin use for White participants vs. participants of Color: A longitudinal online survey study
Grant Jones, Matthew X. Lowe, Sandeep M. Nayak, et al.
Journal of Affective Disorders (2024)
Closed Access | Times Cited: 2
The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides
Pablo Mallaroni, Natasha L. Mason, Frederick Vinckenbosch, et al.
Psychopharmacology (2022) Vol. 239, Iss. 6, pp. 1783-1796
Open Access | Times Cited: 11
Psilocybin containing mushrooms: a rapidly developing biotechnology industry in the psychiatry, biomedical and nutraceutical fields
Dominique Strauss, Soumya Ghosh, Zurika Murray, et al.
3 Biotech (2022) Vol. 12, Iss. 12
Open Access | Times Cited: 11
The development of psilocybin therapy for treatment-resistant depression: an update
Anna Borissova, James Rucker
BJPsych Bulletin (2023) Vol. 48, Iss. 1, pp. 38-44
Open Access | Times Cited: 5
Content analysis of Reddit posts about coadministration of selective serotonin reuptake inhibitors and psilocybin mushrooms
Kimberly Sakai, Ellen Bradley, Joseph A. Zamaria, et al.
Psychopharmacology (2024) Vol. 241, Iss. 8, pp. 1617-1630
Closed Access | Times Cited: 1
Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery
Baeleigh VanderZwaag, Albert Garcia‐Romeu, Mauricio A. Garcia‐Barrera
Therapeutic Advances in Psychopharmacology (2024) Vol. 14
Open Access | Times Cited: 1
Further development of a liquid chromatography–high‐resolution mass spectrometry/mass spectrometry‐based strategy for analyzing eight biomarkers in human urine indicating toxic mushroom or Ricinus communis ingestions
Thomas P. Bambauer, Lea Wagmann, Armin Weber, et al.
Drug Testing and Analysis (2021) Vol. 13, Iss. 9, pp. 1603-1613
Closed Access | Times Cited: 11
On the mushrooming reports of “quiet quitting”: Employees’ lifetime psilocybin use predicts their overtime hours worked
Benjamin A. Korman
Journal of Psychoactive Drugs (2023) Vol. 56, Iss. 4, pp. 475-484
Closed Access | Times Cited: 3
Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests
Grant Jones, Maha Al‐Suwaidi, Franchesca Castro‐Ramirez, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 3
Deepening our understanding of psychedelics by expanding psychedelic data collection in the United States National Survey on Drug Use and Health
Brian S. Barnett
Journal of Psychopharmacology (2022) Vol. 36, Iss. 10, pp. 1097-1099
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top